<DOC>
	<DOCNO>NCT02861014</DOCNO>
	<brief_summary>The purpose prospective , multicenter , open-label , efficacy , safety study assess efficacy safety ocrelizumab participant Relapsing Remitting Multiple Sclerosis ( RRMS ) suboptimal response adequate course Disease-Modifying Treatment ( DMT ) . The study consist Screening period ( 4 week ) , Open-label treatment period ( 96 week ; last dose administer Week 72 ) , Follow-up period least 2 year .</brief_summary>
	<brief_title>A Study Ocrelizumab Participants With Relapsing Remitting Multiple Sclerosis ( RRMS ) Who Have Had Suboptimal Response Adequate Course Disease-Modifying Treatment ( DMT )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Have definite diagnosis RRMS , confirm per revise McDonald 2010 criterion Have length disease duration , first symptom , less ( &lt; ) 10 year Have receive two prior DMTs , discontinuation recent DMT due lack efficacy Suboptimal disease control DMT Expanded Disability Status Scale ( EDSS ) 0.0 4.0 , inclusive , Screening For woman childbearing potential : agreement use acceptable birth control method treatment period least 6 month last dose study drug Secondary progressive multiple sclerosis ( SPMS ) history primary progressive progressive relapse multiple sclerosis ( MS ) Inability complete Magnetic Resonance Imaging ( MRI ) procedure Known presence neurological disorder Any concomitant disease may require chronic treatment systemic corticosteroid immunosuppressant course study History currently active primary secondary immunodeficiency History severe allergic anaphylactic reaction humanize murine monoclonal antibody History opportunistic infection History know presence recurrent chronic infection History malignancy Congestive heart failure Known active bacterial , viral , fungal , mycobacterial infection infection , exclude fungal infection nail bed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>